Behavioral neurobiology of anxiety and its treatment

Contents Part I Anxiety Disorders - Clinical Anxiety Disorders Diagnosis: Some History and Controversies . . . . . . . . . . . . . 3 O. Joseph Bienvenu, Lisa A. Wuyek, and Murray B. Stein Epidemiology of Anxiety Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21 Ronald C. Kessler, Ayelet Meron Ruscio, Katherine Shear, and Hans-Ulrich Wittchen Comorbidity in Anxiety Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37 Kathleen Ries Merikangas and Sonja Alsemgeest Swanson Part II Anxiety Disorders - Clinical Neuroscience Genetics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63 Katharina Domschke and Ju¨rgen Deckert Neuroanatomy of Anxiety . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77 Newton Sabino Canteras, Leonardo Barbosa Resstel, Leandro Jose´ Bertoglio, Antonio de Pa´dua Carobrez, and Francisco Silveira Guimara˜es Stress and the Neuroendocrinology of Anxiety Disorders . . . . . . . . . . . . . . . . . . . 97 J.M. Peˆgo, J.C. Sousa, O.F.X. Almeida, and N. Sousa Part III Animal Models Animal Models of Anxiety and Anxiolytic Drug Action . . . . . . . . . . . . . . . . . . . 121 Dallas Treit, Elif Engin, and Kris McEown ix Genetic Approaches to Modeling Anxiety in Animals . . . . . . . . . . . . . . . . . . . . . 161 Laura H. Jacobson and John F. Cryan Part IV Translational Science Behavioral Correlates of Anxiety . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 205 Victoria Risbrough Challenging Anxiety: A Focus on the Specificity of Respiratory Symptoms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 229 M.A. Van Duinen, V. Niccolai, and E.J.L. Griez Functional Neuroanatomy of Anxiety: A Neural Circuit Perspective . . . . 251 Amit Etkin Pharmacological Enhancement of Behavioral Therapy: Focus on Posttraumatic Stress Disorder . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 279 Dennis C. Choi, Barbara O. Rothbaum, Maryrose Gerardi, and Kerry J. Ressler Part V Preclinical and Clinical Psychopharmacology Pharmacological Systems The Pharmacology of Anxiety . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 303 C. Durant, D. Christmas, and D. Nutt GABAA Receptor a2/a3 Subtype-Selective Modulators as Potential Nonsedating Anxiolytics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 331 John R. Atack Antidepressant Treatment in Anxiety Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . 361 Anton Y. Bespalov, Marcel M. van Gaalen, and Gerhard Gross Metabotropic Glutamate Receptors: Their Therapeutic Potential in Anxiety . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 391 Will Spooren, Anne Lesage, Hilde Lavreysen, Fabrizio Gasparini, and Thomas Steckler Developing Small Molecule Nonpeptidergic Drugs for the Treatment of Anxiety Disorders: Is the Challenge Still Ahead? . . . . . . . . . . . . . . . . . . . . . . . 415 Thomas Steckler Cannabinoids and Anxiety . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 429 Fabrı´cio A. Moreira and Carsten T. Wotjak